Prevest Denpro — Q4 FY25 earnings call

Call held 30 May 2025

Management summary

Prevest Denpro delivered a resilient Q4 and FY25, with consolidated revenue growing 13.6% YoY to INR 67.09 crores and PAT increasing 12.51% to INR 18.15 crores, while maintaining strong EBITDA margins. The company is strategically expanding into digital dentistry and strengthening its US presence through Axiodent Incorporation, which saw 14% revenue growth. Despite facing a challenging market and slower growth than initially projected, management remains optimistic about future growth driven by diversification and international expansion.

Highlights

  • FY25 consolidated revenue grew 13.6% YoY to INR 67.09 crores, demonstrating steady progress.

  • EBITDA margins for FY25 remained strong at 38.98%, reflecting effective operational efficiency despite inflationary pressures.

  • PAT increased by 12.51% YoY to INR 18.15 crores, maintaining a healthy PAT margin of 27.06%.

  • Q4 FY25 showed significant momentum with revenue jumping 21.79% from Q3 to INR 19.53 crores and EBITDA margins at 39.03%.

  • Successfully launched three new cutting-edge biomaterials and made a strategic entry into digital dentistry, including 3D printers and scanners, with favorable market response.

Concerns

  • FY25 growth rate of 13.6% is lower than the 30% growth seen in previous years, attributed to challenging market conditions, foreign exchange issues, and underperformance of the Oradox product line.

  • The Oradox product line has not performed as well as anticipated, contributing only INR 50 lakhs in FY25.

  • The company has not met its prior IPO target of INR 150 crores revenue in a couple of years post-listing due to various market factors.

Key financials

3 periods

Q4 FY25

  • Revenue
    ₹19.53 Cr
    QoQ +21.8%
  • EBITDA Margin
    39%

H2

  • FY25 Revenue
    ₹35.56 Cr
    YoY +12.8%
  • FY25 EBITDA Margin
    39.1%

FY25

  • Consolidated Revenue
    ₹67.09 Cr
    YoY +13.2%
  • EBITDA Margin
    39%
  • PAT
    ₹18.15 Cr
    YoY +12.5%
  • PAT Margin
    27.1%

What they filed

Q1 FY27: revenue up 20.9%, net profit up 27.9% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue16 15 18 16 19 +15%18 +23%19 +3%19 +21%
EBITDA6 5 7 5 7 +15%6 +11%7 +6%7 +27%
Net profit5 5 5 4 6 +15%5 +4%6 +13%6 +28%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Capital allocation

medium confidence
  • M&A Axiodent Incorporation Acquisition · Closed

    To enhance brand recognition and overcome 'Made in India' perception in the US market, allowing products to be sold under a US label.

    Revenue from the U.S. has grown to around 14% this year, compared to the last year.

    Actually, we started with the marketing of previous products in the U.S., which are made in India label, but we found that the dentists are not happy with the made in India label. So we decided to incorporate a company in the U.S. So the labels, now the products are made in India for the Axiodent Inc. company. So that's the reason that acceptability of the products is better, and that is the reason we decided that we should have a new company incorporated in U.S., and we do the product manufacturing, but we sell the products through the U.S. company.

Guidance & targets

Product

  • New Product Launches Product · FY26 · High confidence 4 to 5
    Looking ahead, we are expecting to launch at least 4 to 5 new products in the 2025-2026 fiscal year with a focus on performance, safety and clinical excellence.

    — Dr. Sai Kalyan

Revenue

  • Revenue Growth Revenue · FY26 · Low confidence aspire for 30%
    Who would not like to grow 25%, 30%. Everybody wants higher growth. Even we aspire for 30% growth, but certain things are not in our hand.

    — Atul Modi

  • Q4 Revenue Run Rate Revenue · Q4 FY26 · Low confidence maintain INR 18.5 crores
    See, every year, this is our experience. From the last so many years, experience is that always the last quarter is better, but this quarter was extremely good. So as well as the export and domestic. But every year, last quarter will be better than the previous year. This is my experience, my 25 years of experience. Because always there is pressure to do more efficiently and completing the targets. So we always prefer that the financials we can cover up maximum sale in the last quarter. So, I think always last quarter is better. But this quarter was extremely better. So we will try to make this change this year also.

    — Namrata Modi

Business Growth

  • Digital Dentistry Business Growth Business Growth · 2026 · Medium confidence reach to a better level
    We hope that once now the next year should be a better year for us. We have reached to this level in 1 year, so we should reach to a better level in 2026.

    — Atul Modi

What to watch in Q1 FY26

New Product Launches (FY26)

FY26
Current 0 (for FY26 so far)
Target 4-5 new products

Why it matters

Indicates the company's innovation pipeline and ability to drive future growth.

Looking ahead, we are expecting to launch at least 4 to 5 new products in the 2025-2026 fiscal year with a focus on performance, safety and clinical excellence.

Risks & concerns

  • Challenging market environment and slower growth

    medium

    FY25 growth of 13.6% is lower than previous years due to market deflation, foreign exchange issues, and underperformance of Oradox.

    Management acknowledged

  • Competition from multinational and Chinese companies

    medium

    The dental market is dominated by large multinational players, making it challenging for Prevest Denpro to achieve faster growth.

    Management acknowledged

  • Oradox product line underperformance

    low

    The Oradox product line has not performed as well as anticipated, contributing only INR 50 lakhs in FY25.

    Management acknowledged

  • Potential over-diversification

    low

    Analyst questioned if the company's broad diversification strategy might dilute focus, but management views it as a necessary long-term move for future relevance.

    Analyst deflected

Q&A highlights

6 direct
Not meeting INR 150 crores revenue target post-IPO and 40% margin. Direct
See post-IPO, our growth rate was around 30%. Based on the growth rate, we estimated a revenue for the next 4 to 5 years in the range of INR 100-plus crores, around INR 120 crores and INR 125 crores. But in the last couple of years because of the market deflation, we have a very slow growth, it's around 10%. This year, we have seen a growth of 13% and moreover, the store projected was based on the new product line, which was introduced 2 years back, Oradox. Unfortunately, Oradox has not taken out so well as anticipated. And all these factors have contributed in the slowdown of growth, and we are trying our best to cope-up with the growth rate as the market situations are also improving.

Addresses a significant miss on prior guidance and provides reasons including market conditions and Oradox underperformance.

Asked by Gaurav

Director salaries and their impact on company margins. Direct
See there is no increase in the salary of the directors in the last 5 years. So there is no reason for any change in the salary structure at this stage. Because the promoters have put in 25 years in building this company. And today, they are getting salary around INR 1 crore, which is commensurate with the market salary structure. So we do not see that there is any reason for changing the salary structure at this stage.

Addresses a direct challenge on cost optimization and management compensation, defending current salary levels.

Asked by Gaurav

Company's focus on domestic vs. export market given past foreign exchange issues. Direct
See, right from the beginning in the last 25 years, we have seen that the exports revenue has been more than the domestic revenue. So that trend is still continuing. 60% of the revenues comes from the exports, and 40% revenue comes from the domestic market. So this trend is still continuing, and we are focusing on both the segments. We are focusing on the domestic markets, and as well as the export market so that we have an overall business growth in the domestic as well as in the export market.

Clarifies the company's balanced strategy for both domestic and export markets, confirming export dominance despite past challenges.

Asked by Reena Gattani

US market strategy, rationale for Axiodent Inc., and revenue growth from the US. Direct
U.S. is an interesting market and high-priced market, and it's a big market, and we have got many of our products approved by the U.S. FDA. So we are focusing on the U.S. market, because about 40% of the world's market is from in the U.S. So we have set up a subsidiary company in U.S.A. We have new brands for the U.S. market... And our revenue in the U.S. has grown to around 14% in this year, compared to the last year.

Details the strategic importance of the US market, the reason for the subsidiary, and specific growth achieved in the region.

Asked by Reena Gattani

Pricing strategy and launch timeline for 3D printers. Direct
See the price of our printers will be very competitive in the Indian market. And we have done lot of research on the pricing, and we are very conscious that we have to be very competitive in the market. So the product will be competitive in the Indian market, and comparable with the prices of the printers which was already available in the market. We have done some test marketing, and the response is very favorable, and prices are acceptable to the Indian customers.

Provides insight into the competitive pricing strategy and positive market acceptance for the new 3D printer product line.

Asked by Rahul Dhruv

Marketing and promotional expenses, specifically for exhibitions and travel. Partial
One cost is for exhibitions and marketing expenses, and the other cost is tour and traveling costs, which is related with our marketing person, that is 2.64%, and traveling cost is 1.23%. Total cost is INR 2.64 crores for exhibition and marketing, tour and traveling INR 1.23 crores. This is the total cost.

Provides a partial breakdown of marketing costs, highlighting significant spend on exhibitions and travel, and indicates no major increase is expected next year.

Asked by Rahul Dhruv

Analyst concern about over-diversification and being 'everything for everybody'. Direct
See, our company is not the only company who is so much diversified. There are many companies worldwide who have such a wide and wide portfolio. They cover digital dentistry, they cover materials, they cover equipment, they cover instruments, everything. It's not that we are the first company who are doing such a type of diversified business portfolio. R&D is very important part of any business who has to sustain for a long time... If we start developing today, we have to make a start someday. We cannot wait, if we start after 5 years, so we will be nowhere. If we are starting digital dentistry, which is going to be a very big business in the next 10 years. We cannot wait for 10 years that we will start digital dentistry business after 10 years.

Addresses a critical analyst concern about potential dilution of focus due to diversification, with management defending it as a necessary long-term strategy for future growth and competitiveness.

Asked by Rahul Dhruv

3 min read 6 chapters

Detailed narrative

Q4 and FY25 Financial Performance Overview

Prevest Denpro reported a consolidated revenue of INR 67.09 crores for FY25, marking a 13.6% growth over the previous year's INR 59.29 crores. Domestic sales contributed significantly with a 13% increase, while exports grew by 10% year-on-year. The company maintained strong operational efficiency, with EBITDA margins holding steady at 38.98% for FY25, compared to 38.30% last year. Net profit after tax (PAT) for the year stood at INR 18.15 crores, reflecting a 12.51% growth and a healthy PAT margin of 27.06%. The fourth quarter was particularly strong, with revenue reaching INR 19.53 crores, a 21.79% jump from Q3, and EBITDA margins at 39.03%.

Strategic Shift to Digital Dentistry

The company has made a bold move into digital dentistry, building on its 3D resin portfolio launched last year. This involves developing advanced 3D printers and scanners, combining in-house R&D with strategic partnerships with global suppliers. Management believes digital dentistry will be a significant growth area, with the global market projected to reach $17.9 billion by 2033, and sees this as a natural progression for the company. They aim to offer a complete end-to-end digital workflow solution for dental clinics and labs.

International Expansion and US Market Focus

Prevest Denpro is actively expanding its international footprint, with exports growing 10% this year. A key focus is the US market, which accounts for approximately 40% of the global dental market. To enhance brand recognition and overcome the 'Made in India' perception, the company incorporated Axiodent Incorporation in the US, which saw its revenue grow by 14% this year. They are also pursuing private labeling partnerships and contract manufacturing opportunities in the US, leveraging their FDA-approved products.

R&D and New Product Development

The R&D team is focused on innovation and translation, successfully developing three new cutting-edge biomaterials: Crysta Axis (strontium-enriched restorative material), Caries Cure SDF (silver diamine fluoride system), and Crysta LC RMGI (resin-modified glass ionomer). These products are 100% indigenously developed. The company plans to launch 4 to 5 new products in FY26, emphasizing performance, safety, and clinical excellence. Additionally, they are scaling up production of core biomaterials like hydroxyapatite and tricalcium phosphate for internal use and global commercialization to other manufacturers and medical device suppliers.

Market Challenges and Growth Outlook

While FY25 saw 13.6% revenue growth, it was lower than the 30% growth rates seen post-IPO, attributed to market deflation, foreign exchange crises in some international markets, and the slower-than-anticipated uptake of the Oradox product line, which contributed only INR 50 lakhs. Despite these challenges, management remains optimistic, aspiring for 25-30% growth in the coming year, driven by stabilization in international markets, momentum in digital dentistry, and the US operations. They emphasize a long-term view, prioritizing consistent profitable growth over unsustainable short-term gains.

Operational Efficiency and Cost Management

The company has focused on strengthening its fundamentals by implementing lean manufacturing principles, upgrading ERP systems, and optimizing its supply chain network. These initiatives have resulted in better asset utilization, reduced working capital, and improved production flexibility. This focus on efficiency helped maintain EBITDA margins at 38.98% for FY25 despite inflationary pressures on raw materials and logistics. Management stated that director salaries have not increased in the last 5 years and are commensurate with market standards, indicating a focus on business growth rather than cost-cutting in this area.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls